Status:
UNKNOWN
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
Lead Sponsor:
American College of Radiology Imaging Network
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Neuroblastoma
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease. PURPOSE: This clinical trial is studying whole-body...
Detailed Description
OBJECTIVES: Primary * Compare non-inferior diagnostic performance of whole-body MRI (i.e., combination of turbo short-tau inversion-recovery (STIR) and out-of-phase imaging) vs conventional imaging ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Confirmed diagnosis OR newly diagnosed mass strongly suspected to represent 1 of the following:
- Rhabdomyosarcoma
- Ewing's sarcoma family of tumors
- Neuroblastoma
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- All imaging examinations (e.g., CT scan, MRI, or scintigraphy) must be performed within 14 days of each other and within 2 months of any diagnostic or operative procedure
- Whole body MRI and positron emission tomography (PET) scanning (if PET scan is being done) must be done before treatment
- Prior CT scan, conventional MRI, bone scintigraphy, gallium scintigraphy, or meta-iodobenzylguanidine (MIBG) scintigraphy performed at outside institutions allowed provided the same technical standards specified in this study were practiced
- Bone scintigraphy required for patients with neuroblastoma, rhabdomyosarcoma, or other sarcomas
- Gallium scintigraphy not required in lymphoma patients if PET scan is performed
- No CNS primary tumor
- PATIENT CHARACTERISTICS:
- Age
- 21 and under
- Performance status
- Not specified
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- Cardiovascular
- No active cardiac pacemakers
- Other
- Not pregnant or nursing
- No prior malignancy
- No uncontrolled diabetes mellitus (for patients undergoing optional PET)
- Patients with controlled diabetes mellitus must have a fasting blood glucose no greater than 200 mg/dL
- No contraindications to MRI or CT scan (e.g., intracranial vascular clips)
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- Not specified
- Endocrine therapy
- Not specified
- Radiotherapy
- Not specified
- Surgery
- Prior biopsy or surgery allowed provided no more than 2 months has passed since the procedure
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
226 Patients enrolled
Trial Details
Trial ID
NCT00072488
Start Date
October 1 2004
Last Update
June 8 2010
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
2
Children's Hospital Center for Cancer and Blood Disorders
Aurora, Colorado, United States, 80045
3
Nemours Children's Clinic
Jacksonville, Florida, United States, 32207-8482
4
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States, 33136